General Announcement::GPL Announces Results from New Analysis of Pooled Data on Ryaltris

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
26-Feb-2019 11:56:50
Status
New
Announcement Sub Title
GPL Announces Results from New Analysis of Pooled Data on Ryaltris
Announcement Reference
SG190226OTHRZ4UZ
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
26/02/2019 09:24:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris , an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting

Attachments

PR_SGX_26022019_SIGNED.pdf
Total size =219K